Respiratory Syncytial Virus (RSV) Burden in Infants in the Kingdom of Saudi Arabia and the Impact of All-Infant RSV Protection: A Modeling Study
Open Access
- 15 February 2024
- journal article
- research article
- Published by Springer Nature in Advances in Therapy
- Vol. 41 (4) , 1419-1435
Abstract
Introduction Respiratory syncytial virus (RSV) represents a considerable burden on the healthcare system and hospital resources. This study explored the impact of universal immunoprophylaxis with long-acting monoclonal antibody (nirsevimab) during infants’ first RSV season on RSV-induced health events and related costs in the Kingdom of Saudi Arabia (KSA). Methods The burden of RSV-induced health events and related costs under the current standard of practice (SoP) and the impact of universal immunoprophylaxis with nirsevimab was estimated using a static decision-analytic model in a cohort of infants experiencing their first RSV season in the KSA. The model estimated hospital admissions (including pediatric intensive care unit [PICU] admissions and mechanical ventilation [MV]), emergency room (ER) visits, primary care (PC) visits, long-term sequelae, and RSV mortality. Results The model estimated that under the current SoP, RSV results in 17,179–19,607 hospitalizations (including 2932–3625 PICU and 172–525 MV admissions), 57,654–191,115 ER visits, 219,053–219,970 PC visits, 14 deaths, 12,884–14,705 cases of recurrent wheezing, and a total cost of SAR 480–619 million. Universal nirsevimab immunoprophylaxis was estimated to avert 58% of hospitalizations (58% PICU admissions, 58% MV episodes), 53% of ER visits, 53% of PC visits, 58% of episodes of recurrent wheezing, 8 deaths, and result in savings of SAR 274–343 million in total healthcare cost. Conclusion Compared with current SoP, an nirsevimab immunoprophylaxis strategy in the KSA for all infants during their first RSV season was estimated to dramatically decrease healthcare resource use, and economic burden associated with RSV.Keywords
Funding Information
- Sanofi
- AstraZeneca
This publication has 26 references indexed in Scilit:
- Respiratory syncytial virus hospitalization in children in northern SpainPLOS ONE, 2018
- Bronchiolitis in children: The Saudi initiative of bronchiolitis diagnosis, management, and prevention (SIBRO)Annals of Thoracic Medicine, 2018
- Modelling estimates of the burden of respiratory syncytial virus infection in children in the UKBMJ Open, 2016
- Population-based Analysis of Bronchiolitis Epidemiology in Valencia, SpainThe Pediatric Infectious Disease Journal, 2016
- Respiratory Syncytial Virus–Associated Hospitalizations Among Children Less Than 24 Months of AgePediatrics, 2013
- Epidemiology of hospitalization for acute bronchiolitis in children: differences between RSV and non-RSV bronchiolitisEuropean Journal of Clinical Microbiology & Infectious Diseases, 2012
- The Burden of Respiratory Syncytial Virus Infection in Young ChildrenNew England Journal of Medicine, 2009
- Seasonality of long term wheezing following respiratory syncytial virus lower respiratory tract infectionThorax, 2004
- Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart diseaseThe Journal of Pediatrics, 2003
- Asthma and Immunoglobulin E Antibodies After Respiratory Syncytial Virus Bronchiolitis: A Prospective Cohort Study With Matched ControlsPediatrics, 1995